- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03811327
Zero-time Exercise for Depression
March 9, 2020 updated by: Fiona YY Ho, Chinese University of Hong Kong
Zero-time Exercise for Depression: A Pilot Randomised Controlled Trial
This study will examine the feasibility and effectiveness of a new lifestyle-integrated exercise, viz.
Zero-time Exercise (ZTEx), for the management of depressive symptoms in Chinese adults in Hong Kong.
ZTEx refers to the integration of simple strength- and stamina-enhancing physical activity into daily life, which can be done anytime, anywhere and by anyone.
Depression is often accompanied by a tendency to sedentary behaviours and sleep disturbances, and sedentary lifestyles is associated with depression.
The conventional psychological treatment approach for depression, viz.
Cognitive Behavioural Therapy (CBT), emphasises the relationship between activity and mood.
One of the treatment components in CBT for depression, viz.
Behavioural Activation (BA), aims to promote activity engagement that are reinforcing and consistent with the long-term goals in reducing sedentary behaviour and increasing physical activity.
The simple and brief ZTEx uses a foot-in-the-door approach to initiate simple behaviour change as an entry-level step for facilitating BA for participants with depression.
A pilot randomized controlled trial (RCT) has shown some evidence on the effectiveness of ZTEx on improving insomnia.
However, investigators have found no RCT on the effectiveness of ZTEx for the management of depressive symptoms.
Study Overview
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sha Tin, Hong Kong
- The Chinese University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Hong Kong residents aged 18-65 years
- Cantonese language fluency
- Patient Health Questionnaire (PHQ-9) score ≥ 10 and ≤ 14; and
- Willingness to provide informed consent and comply with the trial protocol.
Exclusion Criteria:
- Pregnancy;
- Have high levels of suicidal ideation (referral information to professional services will be provided);
- Unstable psychotropic drugs within 2 weeks before study entry and throughout the treatment phase;
- Current involvement in psychotherapy for depression;
- Having unsafe conditions and are not recommended for exercising by physicians; and
- Major psychiatric, medical or neurocognitive disorders that would make participation infeasible or interfere with the adherence to physical exercising.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Zero-time Exercise group
|
A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
|
No Intervention: Waitlist group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
The PHQ-9, a 20-item questionnaire used for screening, diagnosing, monitoring and measuring the severity of depression, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, moderately severe and severe depression
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A 14-item self-rating scale that measures anxiety and depression in both hospital and community settings.
It is divided into an Anxiety subscale (HADS-A) and a Depression subscale (HADS-D) both containing seven intermingled items.
It is for screening purpose and not meant to be a diagnostic tool.
HADS scores of 8-10, 11-14, and 15-21 represent mild, moderate, and severe anxiety and depression separately
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in Insomnia Severity Index (ISI)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A 7-item scale designed to evaluate perceived insomnia severity.
Ratings on the 5-point Likert scale are obtained on the perceived severity of sleep-onset, sleep-maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeably of impairment attributed to the sleep problem, and level of distress caused by the sleep problem.
Total score categories: 0-7 is no clinically significant insomnia, 8-14 is subthreshold insomnia,15-21 is clinical insomnia (moderate severity), and 22-28 is clinical insomnia (severe)
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in Multidimensional Fatigue Inventory (MFI)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A 20-item self-report instrument designed to measure fatigue.
Ratings on a 5-point Likert scale are obtained on the dimensions of general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity.
Scores on each subscale range from 4 to 20, with higher scores indicating greater fatigue
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in International Physical Activities Questionnaire - Chinese version (IPAQ-C)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
IPAQ-C is a short form questionnaire assessing walking, moderate-intensity activities and vigorous-intensity activities undertaken across 4 domains - leisure time physical activity, domestic and gardening (yard) activities, work-related physical activity and transport-related physical activity.
Both continuous and categorical scores can be represented.
For continuous scoring, the items provide separate scores on the three specific types of activities.
Computation of the total score requires summation of the duration (in minutes) and frequency (days) of the three specific type of activities.
Median minutes/week or median MET-minutes/week is derived for each type of activity - Walking = 3.3 METs, Moderate PA = 4.0 METs and Vigorous PA = 8.0 METs.
For categorical scoring, category 1 represents the lowest level of physical activity, category 2 represents moderate level of physical activity, and category 3 represents the highest level of physical activity.
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in Short Form (Six-Dimension) Health Survey - The Chinese (Hong Kong) Version (SF-6D)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A preference-based single index measure of health.
A six-digit number represents each SF-6D health state, each digit denotes the level of one of six SF-6D dimensions: physical functioning, role limitation, social functioning, bodily pain, mental health, and vitality.
The SF-6D index, scored from 0.0 (worst health state) to 1.0 (best health state)
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in Sheehan Disability Scale (SDS)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A 5-item self-report tool for assessing functional impairment in work/school, social life, and family life.
Representation of scores in terms of functional impairment: 0: not at all, 1-3: mildly, 4-6: moderately, 7-9: markedly, 10: extremely
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Change in Ecological momentary assessment (EMA)
Time Frame: Baseline, 1-week post-treatment and 4-week post treatment
|
A smartphone application will be developed and installed in the participant's smartphones for recording the participants' momentary mood, daytime insomnia symptoms as well as activities.
|
Baseline, 1-week post-treatment and 4-week post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Actual)
July 31, 2019
Study Completion (Actual)
August 31, 2019
Study Registration Dates
First Submitted
January 18, 2019
First Submitted That Met QC Criteria
January 18, 2019
First Posted (Actual)
January 22, 2019
Study Record Updates
Last Update Posted (Actual)
March 11, 2020
Last Update Submitted That Met QC Criteria
March 9, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSY005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Zero-time Exercise
-
The Hong Kong Polytechnic UniversityCompletedInsomnia, PrimaryHong Kong
-
The University of Hong KongThe Hong Kong Jockey Club Charities Trust; Caritas Medical Centre, Hong KongCompleted
-
The Hong Kong Polytechnic UniversityCompleted
-
The Hong Kong Polytechnic UniversityCompletedInsomnia, PrimaryHong Kong
-
Mayo ClinicEnrolling by invitation
-
The University of Hong KongUnknown
-
GE HealthcareCompleted
-
P.L.Shupik National Medical Academy of Post-Graduate...CompletedWeight Loss
-
Synthes USA HQ, Inc.Terminated
-
Universidad de GranadaRecruitingObesity | Exercise | Hepatic Steatosis | Time Restricted Feeding | Cardiometabolic SyndromeSpain